Skip to main content
Top

Open Access 06-09-2024 | Amyloidosis | COMMENTARY

Symptoms of Hereditary Transthyretin Amyloidosis: The Patient and Physician Perspective

Authors: Michael Lane, Michael Polydefkis

Published in: Neurology and Therapy

Login to get access

Abstract

This article has been co-authored by a patient living with hereditary transthyretin (ATTRv) amyloidosis and a neurologist. This rare, progressive disease is associated with impairment of multiple organ systems, including the nerves, heart, and the gastrointestinal tract, forcing patients to live with and adapt to a range of debilitating symptoms. Here, the patient and physician discuss how the symptoms of ATTRv amyloidosis profoundly impact day to day life, the difficulties with identifying the disease, and how this effects the diagnosis experience. In recent years, significant advancements have been made in the treatment and management of ATTRv amyloidosis. However, the authors highlight the urgency of increasing awareness of the disease among the wider medical community, as well as in patients who notice the symptoms, to ensure that earlier diagnosis and appropriate treatment are achieved.
Literature
1.
go back to reference Luigetti M, Romano A, Di Paolantonio A, Bisogni G, Sabatelli M. Diagnosis and treatment of hereditary transthyretin amyloidosis (hATTR) polyneuropathy: current perspectives on improving patient care. Ther Clin Risk Manag. 2020;16:109–23.CrossRefPubMedPubMedCentral Luigetti M, Romano A, Di Paolantonio A, Bisogni G, Sabatelli M. Diagnosis and treatment of hereditary transthyretin amyloidosis (hATTR) polyneuropathy: current perspectives on improving patient care. Ther Clin Risk Manag. 2020;16:109–23.CrossRefPubMedPubMedCentral
2.
go back to reference Cambieri C, Libonati L, Moret F, et al. The silent period for small fiber sensory neuropathy assessment in a mixed cohort of transthyretin-mediated amyloidosis. Biomedicines. 2022;10:2073.CrossRefPubMedPubMedCentral Cambieri C, Libonati L, Moret F, et al. The silent period for small fiber sensory neuropathy assessment in a mixed cohort of transthyretin-mediated amyloidosis. Biomedicines. 2022;10:2073.CrossRefPubMedPubMedCentral
3.
go back to reference Carroll A, Dyck PJ, de Carvalho M, et al. Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis. J Neurol Neurosurg Psychiatry. 2022;93(6):668–78.CrossRefPubMed Carroll A, Dyck PJ, de Carvalho M, et al. Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis. J Neurol Neurosurg Psychiatry. 2022;93(6):668–78.CrossRefPubMed
4.
go back to reference Nativi-Nicolau J, Karam C, Khella S, Maurer M. Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness. Heart Fail Rev. 2022;27(3):785–93.CrossRefPubMed Nativi-Nicolau J, Karam C, Khella S, Maurer M. Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness. Heart Fail Rev. 2022;27(3):785–93.CrossRefPubMed
5.
go back to reference Benson M, Dasgupta N, Rao R. Diagnosis and screening of patients with hereditary transthyretin amyloidosis (hATTR): current strategies and guidelines. Ther Clin Risk Manag. 2020;16:749–58.CrossRefPubMedPubMedCentral Benson M, Dasgupta N, Rao R. Diagnosis and screening of patients with hereditary transthyretin amyloidosis (hATTR): current strategies and guidelines. Ther Clin Risk Manag. 2020;16:749–58.CrossRefPubMedPubMedCentral
6.
go back to reference Bentellis I, Amarenco G, Gamé X, et al. Diagnosis and treatment of urinary and sexual dysfunction in hereditary TTR amyloidosis. Clin Auton Res. 2019;29:S65–74.CrossRef Bentellis I, Amarenco G, Gamé X, et al. Diagnosis and treatment of urinary and sexual dysfunction in hereditary TTR amyloidosis. Clin Auton Res. 2019;29:S65–74.CrossRef
7.
go back to reference Lovley A, Raymond K, Guthrie S, Pollock M, Sanchorawala V, White MK. Patient-reported burden of hereditary transthyretin amyloidosis on functioning and well-being. J Patient Rep Outcomes. 2021;5:3.CrossRefPubMedPubMedCentral Lovley A, Raymond K, Guthrie S, Pollock M, Sanchorawala V, White MK. Patient-reported burden of hereditary transthyretin amyloidosis on functioning and well-being. J Patient Rep Outcomes. 2021;5:3.CrossRefPubMedPubMedCentral
8.
go back to reference Barroso FA, Coelho T, Dispenzieri A, et al. Characteristics of patients with autonomic dysfunction in the transthyretin amyloidosis outcomes survey (THAOS). Amyloid. 2022;29(3):175–83.CrossRefPubMed Barroso FA, Coelho T, Dispenzieri A, et al. Characteristics of patients with autonomic dysfunction in the transthyretin amyloidosis outcomes survey (THAOS). Amyloid. 2022;29(3):175–83.CrossRefPubMed
10.
go back to reference Yilmaz A, Bauersachs J, Bengel F, et al. Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK). Clin Res Cardiol. 2021;110:479–506.CrossRefPubMedPubMedCentral Yilmaz A, Bauersachs J, Bengel F, et al. Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK). Clin Res Cardiol. 2021;110:479–506.CrossRefPubMedPubMedCentral
11.
go back to reference Sekijima Y, Nakamura K. Hereditary transthyretin amyloidosis. 2001 Nov 5 [Updated 2024 May 30]. In: GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle. Sekijima Y, Nakamura K. Hereditary transthyretin amyloidosis. 2001 Nov 5 [Updated 2024 May 30]. In: GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle.
12.
go back to reference Obici L, Mussinelli R. Current and emerging therapies for hereditary transthyretin amyloidosis: strides towards a brighter future. Neurotherapeutics. 2021;18:2286–302.CrossRefPubMedPubMedCentral Obici L, Mussinelli R. Current and emerging therapies for hereditary transthyretin amyloidosis: strides towards a brighter future. Neurotherapeutics. 2021;18:2286–302.CrossRefPubMedPubMedCentral
13.
go back to reference Damy T, Adam C, Bridoux F, et al. Amyloidosis from the patient perspective: the French daily impact of amyloidosis study. Amyloid. 2022;29:165–74.CrossRefPubMed Damy T, Adam C, Bridoux F, et al. Amyloidosis from the patient perspective: the French daily impact of amyloidosis study. Amyloid. 2022;29:165–74.CrossRefPubMed
Metadata
Title
Symptoms of Hereditary Transthyretin Amyloidosis: The Patient and Physician Perspective
Authors
Michael Lane
Michael Polydefkis
Publication date
06-09-2024
Publisher
Springer Healthcare
Published in
Neurology and Therapy
Print ISSN: 2193-8253
Electronic ISSN: 2193-6536
DOI
https://doi.org/10.1007/s40120-024-00657-y

Advances in Alzheimer's

Alzheimer's research and care is changing rapidly. Keep up with the latest developments from key international conferences, together with expert insights on how to integrate these advances into practice.

This content is intended for healthcare professionals outside of the UK.

Supported by:
  • Lilly
Developed by: Springer Healthcare IME
Learn more